The Indices of Cardiovascular Magnetic Resonance Derived Atrial Dynamics May Improve the Contemporary Risk Stratification Algorithms in Children with Hypertrophic Cardiomyopathy
- PMID: 33567718
- PMCID: PMC7915130
- DOI: 10.3390/jcm10040650
The Indices of Cardiovascular Magnetic Resonance Derived Atrial Dynamics May Improve the Contemporary Risk Stratification Algorithms in Children with Hypertrophic Cardiomyopathy
Abstract
Introduction: The most efficient risk stratification algorithms are expected to deliver robust and indefectible identification of high-risk children with hypertrophic cardiomyopathy (HCM). Here we compare algorithms for risk stratification in primary prevention in HCM children and investigate whether novel indices of biatrial performance improve these algorithms.
Methods and results: The endpoints were defined as sudden cardiac death, resuscitated cardiac arrest, or appropriate implantable cardioverter-defibrillator discharge. We examined the prognostic utility of classic American College of Cardiology/American Heart Association (ACC/AHA) risk factors, the novel HCM Risk-Kids score and the combination of these with indices of biatrial dynamics. The study consisted of 55 HCM children (mean age 12.5 ± 4.6 years, 69.1% males); seven had endpoints (four deaths, three appropriate ICD discharges). A strong trend (DeLong p = 0.08) was observed towards better endpoint identification performance of the HCM Risk-Kids Model compared to the ACC/AHA strategy. Adding the atrial conduit function component significantly improved the prediction capabilities of the AHA/ACC Model (DeLong p = 0.01) and HCM Risk-Kids algorithm (DeLong p = 0.04).
Conclusions: The new HCM Risk-Kids individualised algorithm and score was capable of identifying high-risk children with very good accuracy. The inclusion of one of the atrial dynamic indices improved both risk stratification strategies.
Keywords: atrial strain; hypertrophic cardiomyopathy; outcome; risk markers.
Conflict of interest statement
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures





Similar articles
-
Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.JAMA Cardiol. 2019 Jul 1;4(7):644-657. doi: 10.1001/jamacardio.2019.1391. JAMA Cardiol. 2019. PMID: 31116360 Free PMC article.
-
A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy.Heart. 2013 Apr;99(8):534-41. doi: 10.1136/heartjnl-2012-303271. Epub 2013 Jan 22. Heart. 2013. PMID: 23339826
-
Validation of the 2020 AHA/ACC Risk Stratification for Sudden Cardiac Death in Chinese Patients With Hypertrophic Cardiomyopathy.Front Cardiovasc Med. 2021 Aug 17;8:691653. doi: 10.3389/fcvm.2021.691653. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34485400 Free PMC article.
-
Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy.Circ Res. 2019 Aug 2;125(4):370-378. doi: 10.1161/CIRCRESAHA.119.315159. Epub 2019 Aug 1. Circ Res. 2019. PMID: 31518168 Review.
-
Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy.Heart Rhythm. 2016 May;13(5):1155-1165. doi: 10.1016/j.hrthm.2015.12.048. Epub 2016 Jan 1. Heart Rhythm. 2016. PMID: 26749314 Review.
Cited by
-
What Aspects of Phenotype Determine Risk for Sudden Cardiac Death in Pediatric Hypertrophic Cardiomyopathy?J Cardiovasc Dev Dis. 2022 Apr 21;9(5):124. doi: 10.3390/jcdd9050124. J Cardiovasc Dev Dis. 2022. PMID: 35621835 Free PMC article. Review.
-
Comparison of Nonclassic and Classic Phenotype of Hypertrophic Cardiomyopathy Focused on Prognostic Cardiac Magnetic Resonance Parameters: A Single-Center Observational Study.Diagnostics (Basel). 2022 Apr 28;12(5):1104. doi: 10.3390/diagnostics12051104. Diagnostics (Basel). 2022. PMID: 35626260 Free PMC article.
References
-
- Maron B.J., Ferrans V.J., Henry W.L., Clark C.E., Redwood D.R., Roberts W.C., Morrow A.G., Epstein S.E. Differences in distribution of myocardial abnormalities in patients with obstructive and nonobstructive asymmetric septal hypertrophy (ASH): Light and electron microscopic findings. Circulation. 1974;50:436–446. doi: 10.1161/01.CIR.50.3.436. - DOI - PubMed
-
- Brouwer W.P., Baars E.N., Tjeerd G., de Boer K., Beek A.M., van der Velden J., van Rossum A.C., Mark B.M.H. In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy. J. Cardiovasc. Magn. Reson. 2014;16:28. doi: 10.1186/1532-429X-16-28. - DOI - PMC - PubMed
-
- Maron B.J., Spirito P., Ackerman M.J., Casey S.A., Semsarian C., Estes N.A.M., III, Shannon K.M., Ashley E.A., Day S.M., Pacileo G., et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2013;61:1527–1535. doi: 10.1016/j.jacc.2013.01.037. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources